ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE)

Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses (the “Offering”).

The oversubscribed Offering is expected to close on or about February 18, 2025, subject to satisfaction of customary closing conditions. Before closing, the new shares will be issued out of the Company’s existing capital band (Kapitalband), bringing the total number of registered shares authorized by the Company as per its Articles of Association up to 53,943,700.

Oculis intends to use the net proceeds from the Offering to advance and accelerate its clinical development pipeline, particularly the development of its novel neuroprotective clinical candidate Privosegtor (OCS-05), as well as for working capital and general corporate purposes.

BofA Securities and Leerink Partners are acting as joint bookrunning managers for the Offering. Pareto Securities is acting as lead manager for the Offering. Arctica Finance is acting as financial advisor for the Offering.

The Offering is being made pursuant to a registration statement on Form F-3, including a base prospectus, that was previously filed with the U.S. Securities and Exchange Commission (“SEC”) on April 1, 2024 and declared effective on April 3, 2024. The shares referred to in this press release are being offered in the United States only by means of a prospectus supplement. Copies of the final prospectus supplement for the Offering and the accompanying prospectus may be obtained, when available, from: BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon, Charlotte, North Carolina 28255-0001, or by email at dg.prospectus_requests@bofa.com or Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105 or by email at syndicate@leerink.com. Investors may also obtain these documents at no cost by visiting the SEC’s website at http://www.sec.gov.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease. Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

About Vi Partners

Vi Partners is the longest-established venture capital firm in Switzerland. For over 20 years, Vi Partners has supported innovative technology and healthcare companies, investing over CHF 350 million in 72 startups. Vi Partners-managed funds are backed by some of Switzerland’s most prominent companies and institutions, including ETH Zurich, ABB, Bühler, Credit Suisse, Hilti, McKinsey, Nestlé, Schindler, Sulzer, Suva, and ZKB, as well as the European Investment Fund and many other institutional investors.